Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.8% – Here’s Why

Palvella Therapeutics, Inc. (NASDAQ:PVLA) shares fell 7.8% on Friday . The company traded as low as $84.66 and last traded at $84.91. 136,058 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 203,700 shares. The stock had previously closed at $92.08.

Analysts Set New Price Targets

A number of analysts have commented on PVLA shares. Chardan Capital boosted their target price on Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. BTIG Research reaffirmed a “buy” rating and set a $192.00 price target on shares of Palvella Therapeutics in a research note on Friday, January 16th. HC Wainwright set a $200.00 price objective on shares of Palvella Therapeutics and gave the company a “buy” rating in a research note on Monday, December 15th. Craig Hallum began coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 target price for the company. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Palvella Therapeutics has an average rating of “Buy” and an average target price of $158.69.

Palvella Therapeutics Trading Down 7.1%

The stock’s 50-day moving average is $97.34 and its 200-day moving average is $69.96. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -32.53 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, equities analysts predict that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of PVLA. Aspiriant LLC purchased a new position in Palvella Therapeutics in the 3rd quarter valued at about $367,000. Frazier Life Sciences Management L.P. increased its position in shares of Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after acquiring an additional 32,388 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Palvella Therapeutics in the second quarter worth about $399,000. Goldman Sachs Group Inc. purchased a new position in Palvella Therapeutics in the first quarter valued at about $533,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in Palvella Therapeutics during the 2nd quarter valued at approximately $37,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.